Payment overview · 2025
General Payments
$250.00
2 reported records · 1 companies
Healthcare provider profile · identity verified
Anming Luo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1821162611
Verified facts
What the public records show
CMS Open Payments records show Anming Luo, M.D. received $250.00 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $250.00 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $250.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $250.00 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 846 | 133 |
| Simvastatin | Simvastatin | 673 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 653 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 117 |
| Vascepa | Icosapent Ethyl | 581 | 84 |
| Metformin Hcl | Metformin Hcl | 554 | 87 |
| Alendronate Sodium | Alendronate Sodium | 493 | 70 |
| Diclofenac Epolamine | Diclofenac Epolamine | 474 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 453 | 70 |
| Omeprazole | Omeprazole | 443 | 86 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 412 | 62 |
| Jardiance | Empagliflozin | 367 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 60 |
| Gabapentin | Gabapentin | 280 | 46 |
| Januvia | Sitagliptin Phosphate | 260 | 32 |
| Donepezil Hcl | Donepezil Hcl | 253 | 43 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 238 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 227 | 33 |
| Trazodone Hcl | Trazodone Hcl | 221 | 40 |
| Finasteride | Finasteride | 214 | 36 |
| Meloxicam | Meloxicam | 193 | 76 |
| Meclizine Hcl | Meclizine Hcl | 189 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 55 |
| Hydrocortisone | Hydrocortisone | 172 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 27 |
| Montelukast Sodium | Montelukast Sodium | 152 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 40 |
| Ketoconazole | Ketoconazole | 146 | 31 |
| Ammonium Lactate | Ammonium Lactate | 143 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 137 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 133 | 40 |
| Mometasone Furoate | Mometasone Furoate | 128 | 42 |
| Allopurinol | Allopurinol | 125 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 118 | 83 |
| Icosapent Ethyl | Icosapent Ethyl | 116 | 29 |
| Glimepiride | Glimepiride | 114 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 14 |
| Halobetasol Propionate | Halobetasol Propionate | 109 | 43 |
| Famotidine | Famotidine | 99 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 98 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 96 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 95 | 21 |
| Levofloxacin | Levofloxacin | 90 | 53 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | suppressed |
| Procto-Med Hc | Hydrocortisone | 85 | 20 |
| Methimazole | Methimazole | 84 | 11 |
| Restasis | Cyclosporine | 81 | 14 |
| Eliquis | Apixaban | 79 | 14 |
| Azelastine Hcl | Azelastine Hcl | 78 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | suppressed |
| Linzess | Linaclotide | 71 | 12 |
| Sucralfate | Sucralfate | 71 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 69 | 11 |
| Enalapril Maleate | Enalapril Maleate | 69 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | suppressed |
| Atenolol | Atenolol | 62 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 14 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 54 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 18 |
| Gemfibrozil | Gemfibrozil | 47 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Repaglinide | Repaglinide | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 13 |
| Valsartan | Valsartan | 40 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Proctozone-Hc | Hydrocortisone | 37 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Ibuprofen | Ibuprofen | 35 | 23 |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Lisinopril | Lisinopril | 34 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Baclofen | Baclofen | 31 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | 14 |
| Celecoxib | Celecoxib | 29 | 12 |
| Cyclosporine | Cyclosporine | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Ciclopirox | Ciclopirox | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 14 |
| Cefdinir | Cefdinir | 23 | 21 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Colchicine | Colchicine | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 15 |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Mesalamine Er | Mesalamine | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $250.00 · 2 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error